hypertension
Conditions
Interventions
telmisaltan:40mg + HCTZ:12.5mg
telmisaltan:40mg + amlodipine:12.5mg
Sponsors
Kobe University Hospital,Division of Cardiology
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: hypertension patients who do not reach the target blood pressure with ARB only.
Exclusion criteria
Exclusion criteria: 1) uncontorable hypertension(DBP>110) 2) secondary hepertension 3) diabetes mellitus patient who are uncontorable(HbA1c>8.0%) or use insulin 4) stroke or myocardial infarction or severe cardiovascular disease within past 3 months 5) severe liver dysfunction 6) severe renal failure(Cr>2.0) 7) malignant disease 8) pregnancy woman 9) patient who can not secrete bille enoughly 10) hypersensivity for telmisaltan or HCTZ 11) hypersensivity for Tiazido type medicine 12) hypersensivity for Ca-blocker 13) patient who are judged inappropriate condition for study by doctor
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| blood pressure after 12 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| laboratory data:WBC,RBC,Hb,Hct,Plt,LDL-C,TG,HDL-C,AST,ALT,LDH,ALP,ganma-GTP,CK,FBS,IRI,Alb,BUN,Cr,UA,Na,K,Cl,PRA,aldsterone,U-Na,U-Cl,U-Cr,U-ALb,hs-CRP,HbA1c | — |
Countries
Japan
Contacts
Public ContactTatsuro Ishida
Kobe University Hospital Cardiology
Outcome results
None listed